İlaçlara Bağlı Miyopatiler

Lee A, editor. Adverse Drug Reactions. 2nd ed. Great Britain: Pharmaceutical Press; 2009.

Sieb JP, Gillessen T. Iatrogenic and toxic myopathies. Muscle Nerve 2003; 27:142.

von Kemp K, Herregodts P, Duynslaeger L, et al. Muscular fibrosis due to chronic intramuscular administration of narcotic analgesics. Acta Clin Belg 1989; 44:383.

Schultzel MM, Johnson MH, Rosenthal HG. Bilateral deltoid myositis ossificans in a weightlifter using anabolic steroids. Orthopedics 2014; 37:e844.

Stricker BH, van Kasteren BJ. Diclofenac-induced isolated myonecrosis and the Nicolau syndrome. Ann Intern Med 1992; 117:1058.

Argov Z. Drug-induced myopathies. Curr Opin Neurol. 2000 Oct;13(5):541-5.

Tocut M, Brenner R, Znadman-Goddard. Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev 2018;17(6):610-6.

Ching JK, Ju JS, Pittman SK, et al. Increased autophagy accelerates colchicine-induced muscle toxicity. Autophagy 2013; 9:2115.

Saliba WR, Elias M. Myopathy from the combination of simvastatin and amiodarone. Eur J Intern Med 2006; 17:148

Fernando Roth R, Itabashi H, Louie J, et al. Amiodarone toxicity: myopathy and neuropathy. Am Heart J 1990; 119:1223.

Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006 Aug;34(2):153-62.

Afifi AK, Bergman RA, Harvey JC. Steroid myopathy. Clinical, histologic and cytologic observations. Johns Hopkins Med J 1968;123:158 73.

Anagnos A, Ruff RL, Kaminski HJ. Endocrine neuromyopathies. Neurol Clin 1997;15:673 96.

Saleh FG, Seidman RJ. Drug-induced myopathy and neuropathy. J Clin Neuromuscul Dis. 2003 Dec;5(2):81-92

Hoffman EP, Nader GA. Balancing muscle hypertrophy and atrophy. Nat Med 2004;10:584 5.

Stitt TN, Drujan D, Clarke BA, et al. The IGF 1/PI3K/Akt pathway prevents expression of muscle atrophy induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004;14:395 403.

Hasselgren PO, Alamdari N, Aversa Z, et al. Corticosteroids and muscle wasting: Role of transcription factors, nuclear cofactors, and hyperacetylation. Curr Opin Clin Nutr Metab Care 2010;13:423 8.

Batchelor TT, Taylor LP, Thaler HT, et al. Steroid myopathy in cancer patients. Neurology 1997;48:1234 8.

Herzog AG. Proximal myopathy associated with inhaled steroids. JAMA 1999;281:37.

Haran M, Schattner A, Kozak N, et al. Acute steroid myopathy: A highly overlooked entity. QJM 2018;111:307 11.

Hirano M, Ott BR, Raps EC, et al. Acute quadriplegic myopathy: A complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology 1992;42:2082 7.

Hermans G, De Jonghe B, Bruyninckx F, et al. Clinical review: Critical illness polyneuropathy and myopathy. Crit Care 2008;12:238.

Gaist D, Rodriguez LA, Huerta C,et al. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology. 2001 Sep;12(5):565-9.

Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid lowering drugs. JAMA 2004;292:2585 90.

Rosenson RS, Baker SK, Jacobson TA, et al. The National Lipid Association’s Muscle Safety Expert Panel. An assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol 2014;8:S58 71.

Sathasivam S, Lecky B. Statin induced myopathy. BMJ. 2008 November 6, 2008;337(nov06_3):a2286-.

Hansen K, Hildebrand, JP, Ferguson EE, et al. Outcomes in 45 patients withh statin associated myopathy. Arch Intern Med. 2005;165:2671-6.

Adverse Drug Reactions Advisory Committee. Australian Adverse Drug Reaction Bulletin. Statins and muscle disorders - be carful with the dose [serial on the Internet]. 2008; 27(3).

Alonso R, Mata N, Mata P. Benefits and risks assessment of simvastatin in familial hypercholesterolaemia. Expert Opinion on Drug Safety. 2005;4(2):171-81.

Bruckert E, Hayem G, Dejager S,et al. Mild to moderate muscular symptoms with high dosage statin therapy in hyperlipidemic patients the PRIMO study. Cardiovasc Drugs Ther 2005;19:403 14.

Catapano AL. Statin induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin. Curr Vasc Pharmacol 2012;10:257 67.

Ronaldson KJ, O'Shea JM, Boyd IW. Risk factors for rhabdomyolysis with simvastatin and atorvastatin. Drug Safety. 2006;29(11):1061-7.

Adverse Drug Reactions Adivsory Committee. Australian Adverse Drug Reactions Bulletin. Risk factors for myopathy and rhadbomyolysis with the statins [serial on the Internet]. 2004; 23(1).

Vaklavas C, Chatzizisis YS, Ziakas A,et al. Molecular basis of statin associated myopathy. Atherosclerosis. 2009;202(1):18-28.

Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin induced myopathy: A meta analysis of randomized controlled trials. Mayo Clin Proc 2015;90:24 34.

Hanai J, Cao P, Tanksale P, et al. The muscle specific ubiquitin ligase atrogin 1/MAFbx mediates statin induced muscle toxicity. J Clin Invest 2007;117:3940 51.

Morikawa S, Murakami T, Yamazaki H, et al. Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins. J Atheroscler Thromb 2005;12:121 31.

Mohassel P, Mammen AL. Anti HMGCR myopathy. J Neuromuscul Dis 2018;5:11 20.

Selva O’Callaghan A, Alvarado Cardenas M, Pinal Fernández I, et al. Statin induced myalgia and myositis: An update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol 2018;14:215 24.

Babu S, Li Y. Statin induced necrotizing autoimmune myopathy. J Neurol Sci 2015;351:13 7.

Rosenson RS, Miller K, Bayliss M, et al. The statin associated muscle symptom clinical index (SAMS CI): Revision for clinical use, content validation, and inter rater reliability. Cardiovasc Drugs Ther 2017;31:179 86.

Taylor BA, Sanchez RJ, Jacobson TA, et al. Application of the statin associated muscle symptoms clinical index to a randomized trial on statin myopathy. J Am Coll Cardiol 2017;70:1680 1

Alsheikh Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. Am J Cardiol 2004;94:935 8.

Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe associated adverse effects: What the clinician needs to know. Int J Clin Pract 2008;62:88 96.

Estes ML, Ewing Wilson D, Chou SM, et al. Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med 1987;82:447 55.

Khosa S, Khanlou N, Khosa GS, et al. Hydroxychloroquine-induced autophagic vacuolar myopathy with mitochondrial abnormalities. Neuropathology 2018;38:646–52.

Cotroneo J, Sleik KM, Rene Rodriguez E, et al. Hydroxychloroquine induced restrictive cardiomyopathy. Eur J Echocardiogr 2007;8:247 51.

Abbasi S, Tarter L, Farzaneh-Far R, et al. Hydroxychloroquine: a treatable cause of cardiomyopathy. J Am Coll Cardiol. 2012;60:786.

Tönnesmann E, Stroehmann I, Kandolf R, et al. Cardiomyopathy caused by longterm treatment with chloroquine: a rare disease, or a rare diagnosis? J Rheumatol. 2012;39:1099-1103.

Costedoat-Chalumeau N, Hulot JS, Amoura Z, et al. Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology. 2007;107:73-80.

Brinkman K & Kakuda TN. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Current Opinion in Infectious Diseases 2000; 13:5–1

Dalakas MC, Illa I, Pezeshkpour GH, et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990;322(16):1098–105.

Cupler EJ, Danon MJ, Jay C, et al. Early features of zidovudine-associated myopathy: histopathological findings and clinical correlations. Acta Neuropathol 1995;90(1):1–6

Kohler JJ, Lewis W. A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen 2007;48:166 72.

Chalmers AC, Greco CM, Miller RG. Prognosis in AZT myopathy. Neurology 1991;41(8):1181–4.

Cupler EJ, Danon MJ, Jay C, et al. Early features of zidovudine-associated myopathy: histopathological findings and clinical correlations. Acta Neuropathol 1995;90(1):1–6.

Benbrik E, Chariot P, Bonavaud S, et al. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J Neurol Sci 1997;149(1):19–25.

Pedrol E, Masane´s F, Ferna´ndez-Sola´ J, et al. Lack of muscle toxicity with didanosine (ddI). Clinical and experimental studies. J Neurol Sci 1996;138(1–2):42–8

Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor related myositis and myocarditis in patients with cancer. Neurology 2018;91:e985 e994.

Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. Eur J Cancer 2017;73:1 8.

Kao JC, Brickshawana A, Liewluck T. Programlanmış hücre ölümü-1 (PD-1) inhibitörlerinin nöromüsküler komplikasyonları. Curr Neurol Neurosci Rep 2018; 18 : 63.

Liewluck T, Kao JC, Mauermann ML. PD-1 inhibitörüyle ilişkili miyopatiler: ortaya çıkan bağışıklık aracılı miyopatiler . J Immunother 2018; 41 : 208–11.

Fellner A, Makranz C, Lotem M, et al. Neurologic complications of immune checkpoint inhibitors. J Neurooncol 2018;137:601 9.

Calabrese L, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol 2018;14(10):569-79.

Brahmer JR, Lacchettı C, Schneıder BJ et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714-68. https://dx.doi.org/10.1200/JCO.2017.77.6385

Schneıder BJ, Naıdoo J, Santomasso BD et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: asco guideline update.J Clin Oncol 2021; 39: 4073-126. https://dx.doi.org/10.1200/JCO.21.01440

Bradley WG, Lassman LP, Pearce GW, et al. The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. J Neurol Sci 1970;10:107 31.

Adenis A, Bouché O, Bertucci F, et al. Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors. Med Oncol 2012;29:3003 8.

Perel Winkler A, Belokovskaya R, Amigues I, et al. A case of docetaxel induced myositis and review of the literature. Case Rep Rheumatol 2015;2015:795242.

Saibil S, Fitzgerald B, Freedman OC, et al. Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey. Current Oncology . 2010; 17 (4):42–47.

Adenis A, Bouche´ O, Bertucci F, et al. Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors. J Med Oncol 2012;29(4):3003–8. http://dx.doi.org/10.1007/s12032-012-0204-1.

Setoguchi S, Higgins JM, Mogun H, et al. Propranolol and the risk of hospitalized myopathy: Translating chemical genomics findings into population-level hypotheses. American heart journal 159:428-433, 2010

Teicher A, Rosenthal T, Kissin E, et al. Labetalol-induced toxic myopathy. Br Med J (Clin Res Ed) 1981;282(6279):1824–5.

Willis JK, Tilton AH, Harkin JC, et al. Reversible myopathy due to labetalol. Pediatr Neurol 1990;6(4):275–6.

Aihara M, Takahashi R, Ohtake T, et al. Pindolol-induced rhabdomyolysis in sarcoid myopathy. Rinsho shinkeigaku. Clinical neurology 30:103- 106, 1990

Imai, Y, Watanabe N, Hashimoto J, et al. Muscle cramps and elevated serum creatine phosphokinase levels induced by beta-adrenoceptor blockers. Eur J Clin Pharmacol. 1995;48:29–34

Lynch GS, Ryall JG: Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiological reviews 88:729-767, 2008

Tomlinson B, Cruickshank J, Hayes Y, et al. Selective beta‐adrenoceptor partial agonist effects of pindolol and xamoterol on skeletal muscle assessed by plasma creatine kinase changes in healthy subjects. British journal of clinical pharmacology 30:665-672, 1990

Pulipaka U, Lacomis D, Omalu B. Amiodarone-induced neuromyopathy: three cases and a review of the literature. J Clin Neuromuscul Dis 2002;3(3): 97–105.

Alsheikh-Ali AA, Karas RH. Adverse events with concomitant amiodarone and statin therapy. Prev Cardiol 2005;8(2):95–7.

Fernando Roth R, Itabashi H, Louie J,et al. Amiodarone toxicity: myopathy and neuropathy. Am Heart J 1990;119:1223 5.

Lewis CA, Boheimer N, Rose P, et al. Myopathy after short term administration of procainamide. Br Med J (Clin Res Ed) 1986;292(6520):593–4.

Agius MA, Zhu S, Fairclough RH. Antirapsyn antibodies in chronic procainamide associated myopathy (CPAM). Ann N Y Acad Sci 1998;841:527–9

Yousuf Bhat Z, Reddy S, Pillai U,et al. Colchicine induced myopathy in a tacrolimus treated renal transplant recipient: Case report and literature review. Am J Ther 2016;23:e614 6.

Kuncl RW, Duncan G, Watson D, et al. Colchicine myopathy and neuropathy. N Engl J Med 1987;316(25):1562–8.

Caglar K, Odabasi Z, Safali M, et al. Colchicine-induced myopathy with myotonia in a patient with chronic renal failure. Clin Neurol Neurosurg 2003; 105(4):274–6.

Teener JW. Inflammatory and toxic myopathy. Semin Neurol 2012;32(5): 491–9.

Baker SK, Goodwin S, Sur M, et al. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve 2004;30(6):799–802.

Rutkove SB, De Girolami U, Preston DC, et al. Myotonia in colchicine myoneuropathy. Muscle Nerve 1996;19(7):870–5.

Fernandez C, Figarella-Branger D, Alla P, et al. Colchicine myopathy: a vacuolar myopathy with selective type I muscle fiber involvement. An immunohistochemical and electron microscopic study of two cases. Acta Neuropathol 2002; 103(2):100–6.

Halla JT, Fallahi S, Koopman WJ. Penicillamine induced myositis. Observations and unique features in two patients and review of the literature. Am J Med 1984;77:719 22.

Morgan GJ, McGuire JL, Ochoa J. Penicillamine-induced myositis in rheumatoid arthritis. Muscle Nerve 1981, 4, 137–140. [CrossRef] [PubMed]

Drosos AA, Christou L, Galanopoulou V, et al. D penicillamine induced myasthenia gravis: Clinical, serological and genetic findings. Clin Exp Rheumatol 1993;11:387 91.

Carroll GJ, Will RK, Peter JB, et al. Penicillamine induced polymyositis and dermatomyositis. J Rheumatol 1987;14:995 1001.

Brunasso AM, Aberer W, Massone C. New onset of dermatomyositis/polymyositis during Anti TNF α therapies: A systematic literature review. Sci World J 2014;2014:1 9.

Moran EM, Mastaglia FL. Cytokines in immune mediated inflammatory myopathies: Cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol 2014;178:405 15.

Atkison P, Joubert G, Barron A, et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995;345:894 6.

Ding H, Li Z, Zhang J. A case report of cyclosporine induced myopathy with subacute muscular atrophy as initial presentation. Medicine (Baltimore) 2019;98:e15206.

Hudson MB, Price SR. Calcineurin: A poorly understood regülatör of muscle mass. Int J Biochem Cell Biol 2013;45:2173 8.

Cirigliano G, Della Rossa A, Tavoni A, et al. Polymyositis occurring during alphainterferon treatment for malignant melanoma: a case report and review of the literature. Rheumatol Int 1999;19(1–2):65–7.

Hengstman GJ, Vogels OJ, ter Laak HJ, et al. Myositis during long-term interferon-alpha treatment. Neurology 2000;54(11):2186.

Greenberg SA. Type 1 interferons and myositis. Arthritis Res Ther 2010; 12(Suppl 1):S4.

Carris NW, Tsalatsanis A, Tipparaju SM, et al. Metformin's impact on statin-associated muscle symptoms: An analysis of ACCORD study data and research materials from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center. Diabetes Obes Metab. 2018 Mar 25. doi: 10.1111/dom.13302.

Keunhyeong Bak, Suhyeon Moon, Minjung Ko, et al. Impact of metformin on statin-assosiated myopathy risk in dislipidemia patients. Pharmacol Res Perspect. 2023:11:e01114. https://doi.org/10.1002/prp2.1114

Slim R, Ben Salem C, Zamy M, Biour M. Pioglitazone induced acute rhabdomyolysis. Diabetes Care 2009;32:e84.

Kennie N, Antoniou T, Berger P. Elevated creatine kinase and myalgia in a patient taking rosiglitazone. Ann Pharmacother 2007;41:521–524

Yokoyama M, Izumiya Y, Yoshizawa M, et al. Acute rhabdomyolysis associated with troglitazone. Diabetes Care 2000;23:421–422

Haan J, Hollander JM, van Duinen SG, et al. Reversible severe myopathy during treatment with finasteride. Muscle Nerve 1997;20(4):502–4

Al-Harbi TM, Kagan J, Tarnopolsky MA. Finasteride-induced myalgia and Hypercalsemia. J Clin Neuromuscul Dis 2008 Dec;10(2):76-8.

Short TG, Young Y. Toxicity of intravenous anaesthetics. Best Pract Res Clin Anaesthesiol 2003;17(1):77–89.

Shimizu J, Tabata T, Tsujita Y, et al. Propofol infusion syndrome complicated with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke‐like episodes: a case report Acute Med Surg. 2020 Jan-Dec; 7(1): e473.

Strickland RA, Murray MJ. Fatal metabolic acidosis in a pediatric patient receiving an infusion of propofol in the intensive care unit: is there a relationship? Crit Care Med 1995;23(2):405–9.

Siniscalchi A, Gallelli L, De Sarro G, et al. Antiepileptic drugs for central poststroke pain management. Pharmacological Research. 2012;65(2):171–175. Epub 2011/09/20.

Siniscalchi A, Gallelli L, Russo E, et al. A review on antiepileptic drugs-dependent fatigue: pathophysiological mechanisms and incidence. European Journal of Pharmacology. 2013;718(1–3):10-16. Epub 2013/09/21.

Engel JN, Mellul VG, Goodman DB. Phenytoin hypersensitivity: a case of severe acute rhabdomyolysis. The American Journal of Medicine. 1986;81(5):928–930.

Santos-Calle FJ, Borras-Blasco J, Navarro-Ruiz A,et al. Unsuspected rhabdomyolysis associated with phenytoin. International Journal of Clinical Pharmacology and Therapeutics. 2005;43(9):436– 440.

Korman LB, Olson MJ. Phenytoin-induced hepatitis, rhabdomyolysis, and renal dysfunction. Clinical Pharmacy. 1989;8(7):514–515. Epub 1989/07/01.

di Russo P, Perrini P, Benedetto N, Siciliano G. Phenytoin-induced rhabdomyolysis: Timely recognition for safely remission. Neurology India. 2016;64(4):793–794.

Pinkston R, Walker LA. Multiorgan system failure caused by valproic acid toxicity. The American Journal of Emergency Medicine. 1997;15(5):504–506.

Roodhooft AM, Van Dam K, Haentjens D, et al. Acute sodium valproate intoxication: occurrence of renal failure and treatment with haemoperfusion-haemodialysis. European Journal of Pediatrics. 1990;149(5):363–364.

Walker CP, Deb S. Rhabdomyolysis and Hepatotoxicity From Valproic Acid: Case Reports. Journal of Pharmacy Practice. 2019:897190019882880.

Chattergoon DS, McGuigan MA, Koren G, Hwang P, Ito S. Multiorgan dysfunction and disseminated intravascular coagulation in children receiving lamotrigine and valproic acid. Neurology. 1997;49(5):1442–1444. Epub 1997/12/31.

Akiyama H, Haga Y, Sasaki N, et al. A case of rhabdomyolysis in which levetiracetam was suspected as the cause. Epilepsy & Behavior Case Reports. 2014;2:152–155.

Isaacson JE, Choe DJ, Doherty MJ. Creatine phosphokinase elevation exacerbated by levetiracetam therapy. Epilepsy & Behavior Case Reports. 2014;2:189–191.

Incecik F, Herguner OM, Besen S, et al. Acute rhabdomyolysis associated with levetiracetam therapy in a child. Acta neurologica Belgica. 2016;116(3):369–370.

Thomas L, Mirza MMF, Shaikh NA, et al. Rhabdomyolysis: a rare adverse effect of levetiracetam. BMJ Case Reports. 2019;12(8). Epub 2019/08/28.

Moinuddin IA. Suspected Levetiracetam-Induced Rhabdomyolysis: A Case Report and Literature Review. The American Journal of Case Reports. 2020;21:e926064.

Tuccori M, Lombardo G, Lapi F, et al. Gabapentin-induced severe myopathy. The Annals of Pharmacotherapy. 2007;41(7):1301–1305.

Bilgir O, Calan M, Bilgir F,et al. Gabapentin-induced rhabdomy¬olysis in a patient with diabetic neuropathy. Intern Med. 2009;48(12):1085–1087.

Falconi D, Tattoli F, Brunetti C, et al. Rhabdomyolysis from gabapentin: a case report. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia. 2015;32(2).

Coupal TM, Chang DR, Pennycooke K, et al. Radiologic Findings in Gabapentin- Induced Myositis. Journal of Radiology Case Reports. 2017;11(4):30–37. Epub 2017/06/02.

Choi MS, Jeon H, Kim HS, et al. A case of gabapentin-induced rhab¬domyolysis requiring renal replacement therapy. Hemodialysis International International Symposium on Home Hemodialysis. 2017;21(1):E4–E8.

Qiu X, Tackett E, Khitan Z. A case of gabapentin overdose induced rhabdomyolysis requiring renal replacement therapy. Clinical Case Reports. 2019;7(8):1596–1599.

Schaub JE, Williamson PJ, Barnes EW, et al. Multisystem adverse reaction to lamotrigine. Lancet. 1994;344(8920):481.

Schwartz MD, Geller RJ. Seizures and altered mental status after lamotrigine overdose. Therapeutic Drug Monitoring. 2007;29(6):843–844.

Karaoulanis SE, Syngelakis M, Fokas K. Rhabdomyolysis after lamotrigine overdose: a case report and review of the literature. Annals of General Psychiatry. 2016;15:6

Boot E, de Haan L. Massive increase in serum creatine kinase during olanzapine and quetiapine treatment, not during treatment with clozapine. Psychopharmacology (Berl) 2000;150:347–348.

Meltzer HY, Cola PA, Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 1996;15:395– 405.

Scelsa SN, Simpson DM, McQuistion HL, et al. Clozapine-induced myotoxicity in patients with chronic psychotic disorders. Neurology 1996;47:1518 –1523.

Meltzer HY. Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message? Psychopharmacology (Berl) 2000;150:349 –350.

Visoiu M, Young MC, Wieland K, et al. Anesthetic drugs and onset of malignant hyperthermia. Anesth Analg 2014;118(2):388–96.

Nelson P, Litman RS. Malignant hyperthermia in children: an analysis of the North american malignant hyperthermia registry. Anesth Analg 2014;118(2):369–74.

Watson AJ, Dalbow MH, Stachura I, et al. Immunologic studies in cimetidine induced nephropathy and polymyositis. N Engl J Med 1983;308(3):142–5.

Hawkins RA, Eckhoff PJ Jr, MacCarter DK, et al. Cimetidine and polymyositis. N Engl J Med 1983;309(3):187–8.

Ralph SP, Bradley FP. Cimetidine-induced dystonic reaction. The Journal of Emergency Medicine, Vol. 21, No. 1, pp. 27–29, 2001

Tanaka K, Nakada T, Abe R, et al. Omeprazole-associated rhabdomyolysis. Crit Care. 2014;18:462.

Tröger U, Reiche I, Jepsen MS, et al. Esomeprazole-induced rhabdomyolysis in a patient with heart failure. Intensive Care Med. 2010;36:1278-1279.

Rajabally YA, Jacob S. Neuropathy associated with lansoprazole treatment. Muscle Nerve. 2005;31:124-125.

Alfonzo CA, Bobo WV, Almond MD. Not a usual suspect; rabeprazole therapy presenting as a severe neuropsychiatric illness: case report. Int J Psychiatry Med. 2003;33:311-315.

Clark DW, Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Eur J Clin Pharmacol. 2006;62:473-479.

Faucheux JM, Tournebize P, Viguier A, et al. Neuromyopathy secondary to omeprazole treatment. Muscle Nerve 1998;21(2):261–2.

Dresser LP, Massey EW, Johnson EE, et al. Ipecac myopathy and cardiomyopathy. Neurol Neurosurg Psychiatry 1993;56(5):560–2.

Vanin JR. Ipecac abuse danger. J Am Coll Health 1992;40: 237–238.

Kuntzer T, Bogousslavsky J, Deruaz JP, et al. Reversible emetine-induced myopathy with ECG abnormalities: a toxic myopathy. J Neurol 1989;236(4): 246–8.

Hartung B, Merk HF, Huckenbeck W et al: Severe generalised rhabdomyolysis with fatal outcome associated with isotretinoin. Int J Legal Med, 2012; 126: 953–5

Chroni E, Monastirli A, Tsambaos D. Neuromuscular adverse effects associated with systemic retinoid dermatotherapy: monitoring and treatment algorithm for clinicians. Drug Saf 2010;33(1):25–34.

Sarifakioglu E, Onur O, Kart H, et al. Acute myopathy and acne fulminans triggered by isotretinoin therapy. Eur J Dermatol 2011;21(5):794–5.

Semira SF: Isotretinoin-induced acute severe myopathy involving pelvic girdle muscles: A case report. Indian J Pharmacol, 2016; 48: 601–3

Mangodt TC, Joos R, Siozopoulou V, et al: Perinuclear antineutrophil cytoplasmic antibody-positive vasculitis, oligoarthritis, tendinitis, and myositis associated with isotretinoin in a 15-year-old boy: Case report and review of literature. Pediatr Dermatol, 2018; 35: e173–77

Hodak E, David M, Gadoth N, Sandbank M. Etretinate induced skeletal muscle damage. Br J Dermatol 1987;116: 623–626.

Lee A, editor. Adverse Drug Reactions. 2nd ed. Great Britain: Pharmaceutical Press; 2009.

Sieb JP, Gillessen T. Iatrogenic and toxic myopathies. Muscle Nerve 2003; 27:142.

von Kemp K, Herregodts P, Duynslaeger L, et al. Muscular fibrosis due to chronic intramuscular administration of narcotic analgesics. Acta Clin Belg 1989; 44:383.

Schultzel MM, Johnson MH, Rosenthal HG. Bilateral deltoid myositis ossificans in a weightlifter using anabolic steroids. Orthopedics 2014; 37:e844.

Stricker BH, van Kasteren BJ. Diclofenac-induced isolated myonecrosis and the Nicolau syndrome. Ann Intern Med 1992; 117:1058.

Argov Z. Drug-induced myopathies. Curr Opin Neurol. 2000 Oct;13(5):541-5.

Tocut M, Brenner R, Znadman-Goddard. Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev 2018;17(6):610-6.

Ching JK, Ju JS, Pittman SK, et al. Increased autophagy accelerates colchicine-induced muscle toxicity. Autophagy 2013; 9:2115.

Saliba WR, Elias M. Myopathy from the combination of simvastatin and amiodarone. Eur J Intern Med 2006; 17:148

Fernando Roth R, Itabashi H, Louie J, et al. Amiodarone toxicity: myopathy and neuropathy. Am Heart J 1990; 119:1223.

Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006 Aug;34(2):153-62.

Afifi AK, Bergman RA, Harvey JC. Steroid myopathy. Clinical, histologic and cytologic observations. Johns Hopkins Med J 1968;123:158 73.

Anagnos A, Ruff RL, Kaminski HJ. Endocrine neuromyopathies. Neurol Clin 1997;15:673 96.

Saleh FG, Seidman RJ. Drug-induced myopathy and neuropathy. J Clin Neuromuscul Dis. 2003 Dec;5(2):81-92

Hoffman EP, Nader GA. Balancing muscle hypertrophy and atrophy. Nat Med 2004;10:584 5.

Stitt TN, Drujan D, Clarke BA, et al. The IGF 1/PI3K/Akt pathway prevents expression of muscle atrophy induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004;14:395 403.

Hasselgren PO, Alamdari N, Aversa Z, et al. Corticosteroids and muscle wasting: Role of transcription factors, nuclear cofactors, and hyperacetylation. Curr Opin Clin Nutr Metab Care 2010;13:423 8.

Batchelor TT, Taylor LP, Thaler HT, et al. Steroid myopathy in cancer patients. Neurology 1997;48:1234 8.

Herzog AG. Proximal myopathy associated with inhaled steroids. JAMA 1999;281:37.

Haran M, Schattner A, Kozak N, et al. Acute steroid myopathy: A highly overlooked entity. QJM 2018;111:307 11.

Hirano M, Ott BR, Raps EC, et al. Acute quadriplegic myopathy: A complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology 1992;42:2082 7.

Hermans G, De Jonghe B, Bruyninckx F, et al. Clinical review: Critical illness polyneuropathy and myopathy. Crit Care 2008;12:238.

Gaist D, Rodriguez LA, Huerta C,et al. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology. 2001 Sep;12(5):565-9.

Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid lowering drugs. JAMA 2004;292:2585 90.

Rosenson RS, Baker SK, Jacobson TA, et al. The National Lipid Association’s Muscle Safety Expert Panel. An assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol 2014;8:S58 71.

Sathasivam S, Lecky B. Statin induced myopathy. BMJ. 2008 November 6, 2008;337(nov06_3):a2286-.

Hansen K, Hildebrand, JP, Ferguson EE, et al. Outcomes in 45 patients withh statin associated myopathy. Arch Intern Med. 2005;165:2671-6.

Adverse Drug Reactions Advisory Committee. Australian Adverse Drug Reaction Bulletin. Statins and muscle disorders - be carful with the dose [serial on the Internet]. 2008; 27(3).

Alonso R, Mata N, Mata P. Benefits and risks assessment of simvastatin in familial hypercholesterolaemia. Expert Opinion on Drug Safety. 2005;4(2):171-81.

Bruckert E, Hayem G, Dejager S,et al. Mild to moderate muscular symptoms with high dosage statin therapy in hyperlipidemic patients the PRIMO study. Cardiovasc Drugs Ther 2005;19:403 14.

Catapano AL. Statin induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin. Curr Vasc Pharmacol 2012;10:257 67.

Ronaldson KJ, O'Shea JM, Boyd IW. Risk factors for rhabdomyolysis with simvastatin and atorvastatin. Drug Safety. 2006;29(11):1061-7.

Adverse Drug Reactions Adivsory Committee. Australian Adverse Drug Reactions Bulletin. Risk factors for myopathy and rhadbomyolysis with the statins [serial on the Internet]. 2004; 23(1).

Vaklavas C, Chatzizisis YS, Ziakas A,et al. Molecular basis of statin associated myopathy. Atherosclerosis. 2009;202(1):18-28.

Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin induced myopathy: A meta analysis of randomized controlled trials. Mayo Clin Proc 2015;90:24 34.

Hanai J, Cao P, Tanksale P, et al. The muscle specific ubiquitin ligase atrogin 1/MAFbx mediates statin induced muscle toxicity. J Clin Invest 2007;117:3940 51.

Morikawa S, Murakami T, Yamazaki H, et al. Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins. J Atheroscler Thromb 2005;12:121 31.

Mohassel P, Mammen AL. Anti HMGCR myopathy. J Neuromuscul Dis 2018;5:11 20.

Selva O’Callaghan A, Alvarado Cardenas M, Pinal Fernández I, et al. Statin induced myalgia and myositis: An update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol 2018;14:215 24.

Babu S, Li Y. Statin induced necrotizing autoimmune myopathy. J Neurol Sci 2015;351:13 7.

Rosenson RS, Miller K, Bayliss M, et al. The statin associated muscle symptom clinical index (SAMS CI): Revision for clinical use, content validation, and inter rater reliability. Cardiovasc Drugs Ther 2017;31:179 86.

Taylor BA, Sanchez RJ, Jacobson TA, et al. Application of the statin associated muscle symptoms clinical index to a randomized trial on statin myopathy. J Am Coll Cardiol 2017;70:1680 1

Alsheikh Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. Am J Cardiol 2004;94:935 8.

Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe associated adverse effects: What the clinician needs to know. Int J Clin Pract 2008;62:88 96.

Estes ML, Ewing Wilson D, Chou SM, et al. Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med 1987;82:447 55.

Khosa S, Khanlou N, Khosa GS, et al. Hydroxychloroquine-induced autophagic vacuolar myopathy with mitochondrial abnormalities. Neuropathology 2018;38:646–52.

Cotroneo J, Sleik KM, Rene Rodriguez E, et al. Hydroxychloroquine induced restrictive cardiomyopathy. Eur J Echocardiogr 2007;8:247 51.

Abbasi S, Tarter L, Farzaneh-Far R, et al. Hydroxychloroquine: a treatable cause of cardiomyopathy. J Am Coll Cardiol. 2012;60:786.

Tönnesmann E, Stroehmann I, Kandolf R, et al. Cardiomyopathy caused by longterm treatment with chloroquine: a rare disease, or a rare diagnosis? J Rheumatol. 2012;39:1099-1103.

Costedoat-Chalumeau N, Hulot JS, Amoura Z, et al. Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology. 2007;107:73-80.

Brinkman K & Kakuda TN. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Current Opinion in Infectious Diseases 2000; 13:5–1

Dalakas MC, Illa I, Pezeshkpour GH, et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990;322(16):1098–105.

Cupler EJ, Danon MJ, Jay C, et al. Early features of zidovudine-associated myopathy: histopathological findings and clinical correlations. Acta Neuropathol 1995;90(1):1–6

Kohler JJ, Lewis W. A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen 2007;48:166 72.

Chalmers AC, Greco CM, Miller RG. Prognosis in AZT myopathy. Neurology 1991;41(8):1181–4.

Cupler EJ, Danon MJ, Jay C, et al. Early features of zidovudine-associated myopathy: histopathological findings and clinical correlations. Acta Neuropathol 1995;90(1):1–6.

Benbrik E, Chariot P, Bonavaud S, et al. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J Neurol Sci 1997;149(1):19–25.

Pedrol E, Masane´s F, Ferna´ndez-Sola´ J, et al. Lack of muscle toxicity with didanosine (ddI). Clinical and experimental studies. J Neurol Sci 1996;138(1–2):42–8

Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor related myositis and myocarditis in patients with cancer. Neurology 2018;91:e985 e994.

Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. Eur J Cancer 2017;73:1 8.

Kao JC, Brickshawana A, Liewluck T. Programlanmış hücre ölümü-1 (PD-1) inhibitörlerinin nöromüsküler komplikasyonları. Curr Neurol Neurosci Rep 2018; 18 : 63.

Liewluck T, Kao JC, Mauermann ML. PD-1 inhibitörüyle ilişkili miyopatiler: ortaya çıkan bağışıklık aracılı miyopatiler . J Immunother 2018; 41 : 208–11.

Fellner A, Makranz C, Lotem M, et al. Neurologic complications of immune checkpoint inhibitors. J Neurooncol 2018;137:601 9.

Calabrese L, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol 2018;14(10):569-79.

Brahmer JR, Lacchettı C, Schneıder BJ et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714-68. https://dx.doi.org/10.1200/JCO.2017.77.6385

Schneıder BJ, Naıdoo J, Santomasso BD et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: asco guideline update.J Clin Oncol 2021; 39: 4073-126. https://dx.doi.org/10.1200/JCO.21.01440

Bradley WG, Lassman LP, Pearce GW, et al. The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. J Neurol Sci 1970;10:107 31.

Adenis A, Bouché O, Bertucci F, et al. Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors. Med Oncol 2012;29:3003 8.

Perel Winkler A, Belokovskaya R, Amigues I, et al. A case of docetaxel induced myositis and review of the literature. Case Rep Rheumatol 2015;2015:795242.

Saibil S, Fitzgerald B, Freedman OC, et al. Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey. Current Oncology . 2010; 17 (4):42–47.

Adenis A, Bouche´ O, Bertucci F, et al. Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors. J Med Oncol 2012;29(4):3003–8. http://dx.doi.org/10.1007/s12032-012-0204-1.

Setoguchi S, Higgins JM, Mogun H, et al. Propranolol and the risk of hospitalized myopathy: Translating chemical genomics findings into population-level hypotheses. American heart journal 159:428-433, 2010

Teicher A, Rosenthal T, Kissin E, et al. Labetalol-induced toxic myopathy. Br Med J (Clin Res Ed) 1981;282(6279):1824–5.

Willis JK, Tilton AH, Harkin JC, et al. Reversible myopathy due to labetalol. Pediatr Neurol 1990;6(4):275–6.

Aihara M, Takahashi R, Ohtake T, et al. Pindolol-induced rhabdomyolysis in sarcoid myopathy. Rinsho shinkeigaku. Clinical neurology 30:103- 106, 1990

Imai, Y, Watanabe N, Hashimoto J, et al. Muscle cramps and elevated serum creatine phosphokinase levels induced by beta-adrenoceptor blockers. Eur J Clin Pharmacol. 1995;48:29–34

Lynch GS, Ryall JG: Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiological reviews 88:729-767, 2008

Tomlinson B, Cruickshank J, Hayes Y, et al. Selective beta‐adrenoceptor partial agonist effects of pindolol and xamoterol on skeletal muscle assessed by plasma creatine kinase changes in healthy subjects. British journal of clinical pharmacology 30:665-672, 1990

Pulipaka U, Lacomis D, Omalu B. Amiodarone-induced neuromyopathy: three cases and a review of the literature. J Clin Neuromuscul Dis 2002;3(3): 97–105.

Alsheikh-Ali AA, Karas RH. Adverse events with concomitant amiodarone and statin therapy. Prev Cardiol 2005;8(2):95–7.

Fernando Roth R, Itabashi H, Louie J,et al. Amiodarone toxicity: myopathy and neuropathy. Am Heart J 1990;119:1223 5.

Lewis CA, Boheimer N, Rose P, et al. Myopathy after short term administration of procainamide. Br Med J (Clin Res Ed) 1986;292(6520):593–4.

Agius MA, Zhu S, Fairclough RH. Antirapsyn antibodies in chronic procainamide associated myopathy (CPAM). Ann N Y Acad Sci 1998;841:527–9

Yousuf Bhat Z, Reddy S, Pillai U,et al. Colchicine induced myopathy in a tacrolimus treated renal transplant recipient: Case report and literature review. Am J Ther 2016;23:e614 6.

Kuncl RW, Duncan G, Watson D, et al. Colchicine myopathy and neuropathy. N Engl J Med 1987;316(25):1562–8.

Caglar K, Odabasi Z, Safali M, et al. Colchicine-induced myopathy with myotonia in a patient with chronic renal failure. Clin Neurol Neurosurg 2003; 105(4):274–6.

Teener JW. Inflammatory and toxic myopathy. Semin Neurol 2012;32(5): 491–9.

Baker SK, Goodwin S, Sur M, et al. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve 2004;30(6):799–802.

Rutkove SB, De Girolami U, Preston DC, et al. Myotonia in colchicine myoneuropathy. Muscle Nerve 1996;19(7):870–5.

Fernandez C, Figarella-Branger D, Alla P, et al. Colchicine myopathy: a vacuolar myopathy with selective type I muscle fiber involvement. An immunohistochemical and electron microscopic study of two cases. Acta Neuropathol 2002; 103(2):100–6.

Halla JT, Fallahi S, Koopman WJ. Penicillamine induced myositis. Observations and unique features in two patients and review of the literature. Am J Med 1984;77:719 22.

Morgan GJ, McGuire JL, Ochoa J. Penicillamine-induced myositis in rheumatoid arthritis. Muscle Nerve 1981, 4, 137–140. [CrossRef] [PubMed]

Drosos AA, Christou L, Galanopoulou V, et al. D penicillamine induced myasthenia gravis: Clinical, serological and genetic findings. Clin Exp Rheumatol 1993;11:387 91.

Carroll GJ, Will RK, Peter JB, et al. Penicillamine induced polymyositis and dermatomyositis. J Rheumatol 1987;14:995 1001.

Brunasso AM, Aberer W, Massone C. New onset of dermatomyositis/polymyositis during Anti TNF α therapies: A systematic literature review. Sci World J 2014;2014:1 9.

Moran EM, Mastaglia FL. Cytokines in immune mediated inflammatory myopathies: Cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol 2014;178:405 15.

Atkison P, Joubert G, Barron A, et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995;345:894 6.

Ding H, Li Z, Zhang J. A case report of cyclosporine induced myopathy with subacute muscular atrophy as initial presentation. Medicine (Baltimore) 2019;98:e15206.

Hudson MB, Price SR. Calcineurin: A poorly understood regülatör of muscle mass. Int J Biochem Cell Biol 2013;45:2173 8.

Cirigliano G, Della Rossa A, Tavoni A, et al. Polymyositis occurring during alphainterferon treatment for malignant melanoma: a case report and review of the literature. Rheumatol Int 1999;19(1–2):65–7.

Hengstman GJ, Vogels OJ, ter Laak HJ, et al. Myositis during long-term interferon-alpha treatment. Neurology 2000;54(11):2186.

Greenberg SA. Type 1 interferons and myositis. Arthritis Res Ther 2010; 12(Suppl 1):S4.

Carris NW, Tsalatsanis A, Tipparaju SM, et al. Metformin's impact on statin-associated muscle symptoms: An analysis of ACCORD study data and research materials from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center. Diabetes Obes Metab. 2018 Mar 25. doi: 10.1111/dom.13302.

Keunhyeong Bak, Suhyeon Moon, Minjung Ko, et al. Impact of metformin on statin-assosiated myopathy risk in dislipidemia patients. Pharmacol Res Perspect. 2023:11:e01114. https://doi.org/10.1002/prp2.1114

Slim R, Ben Salem C, Zamy M, Biour M. Pioglitazone induced acute rhabdomyolysis. Diabetes Care 2009;32:e84.

Kennie N, Antoniou T, Berger P. Elevated creatine kinase and myalgia in a patient taking rosiglitazone. Ann Pharmacother 2007;41:521–524

Yokoyama M, Izumiya Y, Yoshizawa M, et al. Acute rhabdomyolysis associated with troglitazone. Diabetes Care 2000;23:421–422

Haan J, Hollander JM, van Duinen SG, et al. Reversible severe myopathy during treatment with finasteride. Muscle Nerve 1997;20(4):502–4

Al-Harbi TM, Kagan J, Tarnopolsky MA. Finasteride-induced myalgia and Hypercalsemia. J Clin Neuromuscul Dis 2008 Dec;10(2):76-8.

Short TG, Young Y. Toxicity of intravenous anaesthetics. Best Pract Res Clin Anaesthesiol 2003;17(1):77–89.

Shimizu J, Tabata T, Tsujita Y, et al. Propofol infusion syndrome complicated with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke‐like episodes: a case report Acute Med Surg. 2020 Jan-Dec; 7(1): e473.

Strickland RA, Murray MJ. Fatal metabolic acidosis in a pediatric patient receiving an infusion of propofol in the intensive care unit: is there a relationship? Crit Care Med 1995;23(2):405–9.

Siniscalchi A, Gallelli L, De Sarro G, et al. Antiepileptic drugs for central poststroke pain management. Pharmacological Research. 2012;65(2):171–175. Epub 2011/09/20.

Siniscalchi A, Gallelli L, Russo E, et al. A review on antiepileptic drugs-dependent fatigue: pathophysiological mechanisms and incidence. European Journal of Pharmacology. 2013;718(1–3):10-16. Epub 2013/09/21.

Engel JN, Mellul VG, Goodman DB. Phenytoin hypersensitivity: a case of severe acute rhabdomyolysis. The American Journal of Medicine. 1986;81(5):928–930.

Santos-Calle FJ, Borras-Blasco J, Navarro-Ruiz A,et al. Unsuspected rhabdomyolysis associated with phenytoin. International Journal of Clinical Pharmacology and Therapeutics. 2005;43(9):436– 440.

Korman LB, Olson MJ. Phenytoin-induced hepatitis, rhabdomyolysis, and renal dysfunction. Clinical Pharmacy. 1989;8(7):514–515. Epub 1989/07/01.

di Russo P, Perrini P, Benedetto N, Siciliano G. Phenytoin-induced rhabdomyolysis: Timely recognition for safely remission. Neurology India. 2016;64(4):793–794.

Pinkston R, Walker LA. Multiorgan system failure caused by valproic acid toxicity. The American Journal of Emergency Medicine. 1997;15(5):504–506.

Roodhooft AM, Van Dam K, Haentjens D, et al. Acute sodium valproate intoxication: occurrence of renal failure and treatment with haemoperfusion-haemodialysis. European Journal of Pediatrics. 1990;149(5):363–364.

Walker CP, Deb S. Rhabdomyolysis and Hepatotoxicity From Valproic Acid: Case Reports. Journal of Pharmacy Practice. 2019:897190019882880.

Chattergoon DS, McGuigan MA, Koren G, Hwang P, Ito S. Multiorgan dysfunction and disseminated intravascular coagulation in children receiving lamotrigine and valproic acid. Neurology. 1997;49(5):1442–1444. Epub 1997/12/31.

Akiyama H, Haga Y, Sasaki N, et al. A case of rhabdomyolysis in which levetiracetam was suspected as the cause. Epilepsy & Behavior Case Reports. 2014;2:152–155.

Isaacson JE, Choe DJ, Doherty MJ. Creatine phosphokinase elevation exacerbated by levetiracetam therapy. Epilepsy & Behavior Case Reports. 2014;2:189–191.

Incecik F, Herguner OM, Besen S, et al. Acute rhabdomyolysis associated with levetiracetam therapy in a child. Acta neurologica Belgica. 2016;116(3):369–370.

Thomas L, Mirza MMF, Shaikh NA, et al. Rhabdomyolysis: a rare adverse effect of levetiracetam. BMJ Case Reports. 2019;12(8). Epub 2019/08/28.

Moinuddin IA. Suspected Levetiracetam-Induced Rhabdomyolysis: A Case Report and Literature Review. The American Journal of Case Reports. 2020;21:e926064.

Tuccori M, Lombardo G, Lapi F, et al. Gabapentin-induced severe myopathy. The Annals of Pharmacotherapy. 2007;41(7):1301–1305.

Bilgir O, Calan M, Bilgir F,et al. Gabapentin-induced rhabdomy¬olysis in a patient with diabetic neuropathy. Intern Med. 2009;48(12):1085–1087.

Falconi D, Tattoli F, Brunetti C, et al. Rhabdomyolysis from gabapentin: a case report. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia. 2015;32(2).

Coupal TM, Chang DR, Pennycooke K, et al. Radiologic Findings in Gabapentin- Induced Myositis. Journal of Radiology Case Reports. 2017;11(4):30–37. Epub 2017/06/02.

Choi MS, Jeon H, Kim HS, et al. A case of gabapentin-induced rhab¬domyolysis requiring renal replacement therapy. Hemodialysis International International Symposium on Home Hemodialysis. 2017;21(1):E4–E8.

Qiu X, Tackett E, Khitan Z. A case of gabapentin overdose induced rhabdomyolysis requiring renal replacement therapy. Clinical Case Reports. 2019;7(8):1596–1599.

Schaub JE, Williamson PJ, Barnes EW, et al. Multisystem adverse reaction to lamotrigine. Lancet. 1994;344(8920):481.

Schwartz MD, Geller RJ. Seizures and altered mental status after lamotrigine overdose. Therapeutic Drug Monitoring. 2007;29(6):843–844.

Karaoulanis SE, Syngelakis M, Fokas K. Rhabdomyolysis after lamotrigine overdose: a case report and review of the literature. Annals of General Psychiatry. 2016;15:6

Boot E, de Haan L. Massive increase in serum creatine kinase during olanzapine and quetiapine treatment, not during treatment with clozapine. Psychopharmacology (Berl) 2000;150:347–348.

Meltzer HY, Cola PA, Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 1996;15:395– 405.

Scelsa SN, Simpson DM, McQuistion HL, et al. Clozapine-induced myotoxicity in patients with chronic psychotic disorders. Neurology 1996;47:1518 –1523.

Meltzer HY. Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message? Psychopharmacology (Berl) 2000;150:349 –350.

Visoiu M, Young MC, Wieland K, et al. Anesthetic drugs and onset of malignant hyperthermia. Anesth Analg 2014;118(2):388–96.

Nelson P, Litman RS. Malignant hyperthermia in children: an analysis of the North american malignant hyperthermia registry. Anesth Analg 2014;118(2):369–74.

Watson AJ, Dalbow MH, Stachura I, et al. Immunologic studies in cimetidine induced nephropathy and polymyositis. N Engl J Med 1983;308(3):142–5.

Hawkins RA, Eckhoff PJ Jr, MacCarter DK, et al. Cimetidine and polymyositis. N Engl J Med 1983;309(3):187–8.

Ralph SP, Bradley FP. Cimetidine-induced dystonic reaction. The Journal of Emergency Medicine, Vol. 21, No. 1, pp. 27–29, 2001

Tanaka K, Nakada T, Abe R, et al. Omeprazole-associated rhabdomyolysis. Crit Care. 2014;18:462.

Tröger U, Reiche I, Jepsen MS, et al. Esomeprazole-induced rhabdomyolysis in a patient with heart failure. Intensive Care Med. 2010;36:1278-1279.

Rajabally YA, Jacob S. Neuropathy associated with lansoprazole treatment. Muscle Nerve. 2005;31:124-125.

Alfonzo CA, Bobo WV, Almond MD. Not a usual suspect; rabeprazole therapy presenting as a severe neuropsychiatric illness: case report. Int J Psychiatry Med. 2003;33:311-315.

Clark DW, Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Eur J Clin Pharmacol. 2006;62:473-479.

Faucheux JM, Tournebize P, Viguier A, et al. Neuromyopathy secondary to omeprazole treatment. Muscle Nerve 1998;21(2):261–2.

Dresser LP, Massey EW, Johnson EE, et al. Ipecac myopathy and cardiomyopathy. Neurol Neurosurg Psychiatry 1993;56(5):560–2.

Vanin JR. Ipecac abuse danger. J Am Coll Health 1992;40: 237–238.

Kuntzer T, Bogousslavsky J, Deruaz JP, et al. Reversible emetine-induced myopathy with ECG abnormalities: a toxic myopathy. J Neurol 1989;236(4): 246–8.

Hartung B, Merk HF, Huckenbeck W et al: Severe generalised rhabdomyolysis with fatal outcome associated with isotretinoin. Int J Legal Med, 2012; 126: 953–5

Chroni E, Monastirli A, Tsambaos D. Neuromuscular adverse effects associated with systemic retinoid dermatotherapy: monitoring and treatment algorithm for clinicians. Drug Saf 2010;33(1):25–34.

Sarifakioglu E, Onur O, Kart H, et al. Acute myopathy and acne fulminans triggered by isotretinoin therapy. Eur J Dermatol 2011;21(5):794–5.

Semira SF: Isotretinoin-induced acute severe myopathy involving pelvic girdle muscles: A case report. Indian J Pharmacol, 2016; 48: 601–3

Mangodt TC, Joos R, Siozopoulou V, et al: Perinuclear antineutrophil cytoplasmic antibody-positive vasculitis, oligoarthritis, tendinitis, and myositis associated with isotretinoin in a 15-year-old boy: Case report and review of literature. Pediatr Dermatol, 2018; 35: e173–77

Hodak E, David M, Gadoth N, Sandbank M. Etretinate induced skeletal muscle damage. Br J Dermatol 1987;116: 623–626.